FogPharma expands its management team | National company

CAMBRIDGE, Mass .– (BUSINESS WIRE) – November 22, 2021–

FogPharma ®, a biopharmaceutical company pioneering a new class of precision drugs potentially applicable to all therapeutic targets, including those previously considered “non-drug”, today announced the appointments of Lihua Yu, Ph.D., as Chief Data Officer and Keith Orford, MD, Ph.D., as Chief Medical Officer and Executive Vice President of Clinical and Translational Sciences.

Dr Yu, former President and Chief Data Science Officer of H3 Biomedicine Inc., will oversee the development and implementation of FogPharma’s data science strategy across all R&D functions and research programs, and lead the company’s team by creating a diverse portfolio of advanced drugs. for multiple disease-induced targets.

Dr. Orford brings extensive medical and scientific expertise that has led the transition of a number of oncology drug candidates from preclinical translational studies to clinical development, and will oversee translational medicine and clinical development initiatives for FogPharma.

“Lihua and Keith are accomplished drug development executives and we are delighted to welcome them to our growing leadership team,” said Gregory Verdine, Ph.D., Founder and CEO of FogPharma. “It has been a fantastic year of progress at FogPharma – we closed a $ 107 million Series C funding round, continued to develop our multiplexed and machine learning-based drug discovery engine, and advanced our drug discovery programs. cancer control, including our first and in-class direct β-catenin inhibitor. Keith and Lihua will be critical to our future success as we continue to evolve. “

Lihua Yu, Ph.D., as Data Director

Dr. Yu brings more than 20 years of data science experience and leadership in the areas of computational biology, cancer genomics, research informatics, clinical genomics, data and evidence of the real world. Prior to joining FogPharma, Dr Yu was President and Director of Data Science at H3 Biomedicine Inc., a US precision medicine research and development subsidiary of Eisai Co. At H3, she had overall responsibility for research. and business development, and was responsible for driving the expanded use of data and technology and leading the creation of an information sharing / data genomics / cancer engine supporting all phases drug discovery and early clinical development. She led H3 during its transition from a drug discovery company to an early stage drug development company. Prior to H3, she held positions of increasing responsibility at AstraZeneca and was responsible for cancer bioinformatics. Dr Yu obtained his doctorate. in Biomedical Engineering from Boston University under the supervision of Temple Smith, Ph.D., and his Masters and BS in Biomedical Engineering from Tsinghua University in Beijing, China.

Keith Orford, MD, Ph.D., as Chief Medical Officer and Executive Vice President of Clinical and Translational Sciences

Dr Orford joins FogPharma from Calithera Biosciences, where as Medical Director he led the company’s clinical development, clinical operations, biometrics, pharmacovigilance and medical affairs functions. Prior to Calithera, Dr. Orford was Head of Clinical Development in the Immuno-Oncology and Combinations Development Performance Unit at GlaxoSmithKline, where he oversaw clinical development, including several early stage clinical trials with targeted agents and immunotherapies. Prior to GlaxoSmithKline, he worked on early clinical development programs at Merck in several therapeutic areas. Previously, Dr Orford was a researcher and instructor at Massachusetts General Hospital and Harvard Medical School, where he trained in internal medicine and did a postdoctoral fellowship in the lab of David Scadden, MD, studying the epigenetic regulation of cells. hematopoietic and embryonic strains. differentiation. Dr. Orford received his undergraduate degree, MD and PhD. degrees from Georgetown University. His doctoral research elucidated the mechanism by which -catenin is regulated by the Wnt signaling pathway.

About FogPharma ®

FogPharma’s mission is to dramatically reduce the burden of disease on patients and their families by inventing new types of drugs that suppress abnormal physiological processes in ways previously imagined but considered impractical. The company is a pioneer in the discovery, development and commercialization of Helicon ™ peptides, a new class of drugs that uniquely combines the cell permeability and oral dosing option of traditional small molecule drugs with the high specificity, wide accessibility to the target and the arc of rapid discovery of the monoclonal. antibody drugs.

FogPharma was formed out of Harvard University in 2016 by pioneering academic scientist, serial life science entrepreneur, venture capitalist and successful biotech business builder, Dr. Gregory Verdine. FogPharma is headquartered in Cambridge, Massachusetts, and has raised more than $ 180 million to date from leading life science investors. For more information, please visit www.fogpharma.com.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20211122005879/en/

CONTACT: 1AB

Katie Engleman

[email protected]

KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH PHARMACEUTICAL HEALTH

SOURCE: FogPharma

Copyright Business Wire 2021.

PUB: 11/22/2021 08: 00 / DISC: 11/22/2021 08:02

http://www.businesswire.com/news/home/20211122005879/en

Copyright Business Wire 2021.


Source link

Margie D. Carlisle